RxDoctor Payments Data

Kristin Stankevitz, PA

Medical · Saint Paul, MNNPI 1417493008

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.8% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Abbott at 58.6% of the total. Reporting peaked in 2024 at $479 and has fallen 61.1% since, to $186 in 2025. Among medical clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,483in general payments, 2019–2025

Across 40 payments — averaging $37.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$869
  • Boston Scientific$134
  • Edwards Lifesciences$95
  • Cvrx, Inc.$82
  • Novartis$71
  • E.r. Squibb & Sons, L.L.C.$57
  • plus $176 from 8 others

What the payments were for

  • Travel & lodging$181%
  • Food & beverage$1,46699%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,483 in reported general payments places this provider in the 90th percentile of 202 medical providers in Minnesota.

See all medical providers in Minnesota

Medicare billing

Part B allowed, 2024
$22,761
Medicare patients
140
Services billed
267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban98$114,056
EntrestoSacubitril/Valsartan77$109,312
JardianceEmpagliflozin48$48,439
FarxigaDapagliflozin Propanediol45$41,367
XareltoRivaroxaban25$31,005
Torsemide98$4,862
Metoprolol Succinate182$4,077
Bumetanide37$2,556
Potassium Chloride88$2,492
Spironolactone122$1,223
Furosemide140$1,172
Atorvastatin Calcium65$1,026
Losartan Potassium80$896
Rosuvastatin Calcium45$849
Bisoprolol Fumarate21$801

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$71$109,31277 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 202 medical providers in Minnesota.

Other medical in Saint Paul

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →